Establishment and correlation of age specific reference range of psa and psa density in patients of benign prostatic hyperplasia
Keywords:
Prostate Specific Antigen (PSA), Prostate Specific Antigen Density (PSAD), Benign Prostatic Hyperplasia (BPH), Lower Urinary Tract Symptoms (LUTS)Abstract
Prostate specific antigen (PSA) is a 34-kDa serine protease that is produced by both benign and malignant prostatic epithelial cells. PSA has assumed an increasing role in the diagnosis and management of prostate cancer. Both benign and malignant prostate tissue elaborates PSA; therefore the possibility exists for benign processes such as prostatic hyperplasia. Aims and objectives: To estimate serum PSA in 100 patients of Benign Prostatic Hyperplasia (BPH) in various age groups. To estimate the serum PSA in 50 healthy age– matched males. To correlate serum PSA levels in different age groups with volume of prostate gland and prostate density in above 150 cases. Material and Methods: The present hospital based observational and analytical study was conducted in the Department of Biochemistry, Government Medical College, Patiala in collaboration with the Department of Urology Rajindra Hospital, Patiala on 100 patients reporting to Department of Urology with diagnosed BPH and presenting with Lower Urinary Tract Symptoms (LUTS), Rajindra Hospital, Patiala. Results and Conclusion : With increase in age there was increase in size (volume) of the prostate. PSA values were also increased in patients of BPH. An inverse correlation of PSA with PSAdensity was observed in patients of BPH because volume /size of the prostate was increased with increasing age.
Downloads
References
Franklin C. Lowe. Treatment of lower urinary tract symptoms suggestive of benign prostatic hyperplasia: sexual function. BJU INTERNATIONAL.2005; 95(4) .12–8.
Shimizu Shogo, TsounapiPanagiota , Shimizu Takahiro. Lower urinary tract symptoms, benign prostatic hyperplasia/benign prostatic enlargement and erectile dysfunction: Are these conditions related to vascular dysfunction?. International Journal of Urology .2014; 21, 856–64.
Corona Giovanni, Vignozzi Linda, Rastrelli Giulia. Benign Prostatic Hyperplasia: A New Metabolic Disease of the Aging Male and Its Correlation with Sexual Dysfunctions. Hindawi Publishing Corporation International Journal of Endocrinology. 2014,1-14 .
Abrams P, Cardozo L, Fall M ,etal .The standardization of terminology of lower urinary tract function : report from the Standardisation Sub-committee of the International Continence Society.Neurourol Urodyn,2002; 21.167–78.
KupelianV ,WeiJT ,O' Leary MP etal Prevalence of lower urinary tract symptoms and effect on quality of life in a racially and ethnically diverse random sample :the Boston Area Community Health(BACH) Survey . ArchInternMed.2006; 166.2381–7.
Wein Alan J., Kavoussi Louis R., Novick Andrew C., Partin Alan W., Peters Craig A.9 edition.Campbell –Walsh th Urology.81-110
Adhyam Mohan and Kumar Gupta Anish. A Review on the Clinical Utility of PSA in Cancer Prostate. Indian J SurgOncol ; 2012. 3(2):120–9.
Michael K. Brawer. Prostatic Intraepithelial Neoplasia: An Overview. Review in urology.2005;7(3).S11-18
S. Loeb, R. B. Nadler, K. A. Roehl, J. A. V. Antenor, and W. J. Catalona, “Risk of prostate cancer for young men with a prostate speci? c antigen less than their age speci? c median,” Journal of Urology, 2007; 177(5) . 1745–48.
Oesterling J. Age-speci? c reference ranges for serum PSA. The New England Journal of Medicine,1996; 335(5), 345– 6.
Thompson I. M., Pauler D.K, Goodman P.J. et al. Prevalence of prostate cancer among men with a prostate speci? c antigen level=4.0 ng per milliliter. The New England Journal of Medicine,2004; 350 (22), 2239–46.
Baillargeon Jacques, Pollock Brad H,Kristal Alan R. The Association of Body Mass Index and Prostate-Speci? c Antigen in a Population-Based Study. CANCER .2005 ,103 ( 5).1092-5.
Benson MC,WhangIS,PantuckA,et al. Prostate specific antigen density: a means for distinguishing benign prostatic hypertrophy and prostate cancer. J Urol. 1992;147:815-6.
Michael S. Cookson. Prostate Cancer: Screening and Early Detection.2001;8(2).133-40.
Chung BH, Hong SJ,ChoJS,SeongDH.Relationship between serum prostate-specific antigen and prostate volume in Korean men with benign prostatic hyperplasia: a multicentre study. BJU Int. 2006;97(4):742-6.
RahimifarShahrzad, Montazeri Adel. Age-Related Prostate Specific Antigen Reference Ranges in Healthy Northern Iranian Men . Iran.J.Immunol.2018;15 (1).68-73.
UdehEmeka I., NnabugwuIkennaI ,Ozoemena Francis O. , Ugwumba Fred O. , AderibigbeAdesina S. O., Ohayi Samuel R. et al. Prostate-specific antigen density values among patients with symptomatic prostatic enlargement in Nigeria. World Journal of Surgical Oncology.2016;14.1-7.
Eric Seaman, Mattewwhang , Carl. A. Olsson, Aaron Katz ,willian H. Cooner , and Mitchell C . Benson.PSA Density (PSAD) Role in Patient Evaluation and management.253 ?
